+

WO2009082819A8 - Nouveaux dérivés de lupane - Google Patents

Nouveaux dérivés de lupane Download PDF

Info

Publication number
WO2009082819A8
WO2009082819A8 PCT/CA2008/002291 CA2008002291W WO2009082819A8 WO 2009082819 A8 WO2009082819 A8 WO 2009082819A8 CA 2008002291 W CA2008002291 W CA 2008002291W WO 2009082819 A8 WO2009082819 A8 WO 2009082819A8
Authority
WO
WIPO (PCT)
Prior art keywords
formula
treatment
pharmaceutically acceptable
relates
novel
Prior art date
Application number
PCT/CA2008/002291
Other languages
English (en)
Other versions
WO2009082819A1 (fr
Inventor
Christophe Moinet
Liliane Halab
Nathalie Turcotte
Monica Bubenik
Marc Courchesne
Carl Poisson
Oswy Z. Pereira
Paul Nguyen-Ba
Bingcan Liu
Nathalie Chauret
Caroline Cadilhac
Laval Chan Chun Kong
Original Assignee
Virochem Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virochem Pharma Inc. filed Critical Virochem Pharma Inc.
Priority to EP08869088A priority Critical patent/EP2250185A4/fr
Priority to JP2010540997A priority patent/JP2011508748A/ja
Priority to AU2008342537A priority patent/AU2008342537A1/en
Priority to CA2711424A priority patent/CA2711424A1/fr
Priority to CN2008801275273A priority patent/CN101981047A/zh
Priority to MX2010007375A priority patent/MX2010007375A/es
Publication of WO2009082819A1 publication Critical patent/WO2009082819A1/fr
Publication of WO2009082819A8 publication Critical patent/WO2009082819A8/fr
Priority to US12/830,293 priority patent/US8269026B2/en
Priority to US12/830,294 priority patent/US8431556B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de 21-céto triterpènes de formule (I) : R1, X, et Y étant tels que définis dans la description, et des sels et des solvates de ceux-ci pharmaceutiquement acceptables. Ces composés présentent une activité anti-VIH significative. L'invention concerne également des procédés de prévention ou de traitement des infections par le VIH par administration de quantités thérapeutiquement efficaces d'un composé de formule (I), ou d'un sel ou solvate pharmaceutiquement acceptable de celui-ci, à un sujet ayant besoin d'un tel traitement.
PCT/CA2008/002291 2008-01-03 2008-12-23 Nouveaux dérivés de lupane WO2009082819A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP08869088A EP2250185A4 (fr) 2008-01-03 2008-12-23 Nouveaux dérivés de lupane
JP2010540997A JP2011508748A (ja) 2008-01-03 2008-12-23 新規のルパン誘導体
AU2008342537A AU2008342537A1 (en) 2008-01-03 2008-12-23 Novel lupane derivatives
CA2711424A CA2711424A1 (fr) 2008-01-03 2008-12-23 Nouveaux derives de lupane
CN2008801275273A CN101981047A (zh) 2008-01-03 2008-12-23 新的羽扇烷衍生物
MX2010007375A MX2010007375A (es) 2008-01-03 2008-12-23 Nuevos derivados de lupano.
US12/830,293 US8269026B2 (en) 2008-01-03 2010-07-03 Lupane derivatives useful for treating HIV
US12/830,294 US8431556B2 (en) 2008-03-26 2010-07-03 C-21-keto lupane derivatives preparation and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1875908P 2008-01-03 2008-01-03
US61/018,759 2008-01-03
US3966008P 2008-03-26 2008-03-26
US61/039,660 2008-03-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/830,294 Continuation US8431556B2 (en) 2008-03-26 2010-07-03 C-21-keto lupane derivatives preparation and use thereof
US12/830,293 Continuation US8269026B2 (en) 2008-01-03 2010-07-03 Lupane derivatives useful for treating HIV

Publications (2)

Publication Number Publication Date
WO2009082819A1 WO2009082819A1 (fr) 2009-07-09
WO2009082819A8 true WO2009082819A8 (fr) 2009-10-22

Family

ID=40823729

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2008/002291 WO2009082819A1 (fr) 2008-01-03 2008-12-23 Nouveaux dérivés de lupane

Country Status (7)

Country Link
EP (1) EP2250185A4 (fr)
JP (1) JP2011508748A (fr)
CN (1) CN101981047A (fr)
AU (1) AU2008342537A1 (fr)
CA (1) CA2711424A1 (fr)
MX (1) MX2010007375A (fr)
WO (1) WO2009082819A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094191A2 (fr) 2008-01-25 2009-07-30 Chimerix, Inc. Méthodes de traitement d’infections virales
CN102245182B (zh) * 2008-12-11 2014-07-23 盐野义制药株式会社 氨基甲酰基吡啶酮hiv整合酶抑制剂和中间体的合成
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
ES2969969T3 (es) 2010-01-27 2024-05-23 Viiv Healthcare Co Combinaciones de dolutegravir y lamivudina para el tratamiento de la infección por VIH
CA2789195A1 (fr) * 2010-02-11 2011-08-18 Glaxosmithkline Llc Derives de betuline
PT2534150T (pt) 2010-02-12 2017-05-02 Chimerix Inc Métodos para tratar uma infecção viral
CA2797601A1 (fr) 2010-04-26 2011-11-10 Chimerix, Inc. Methodes de traitement d'infections retrovirales et regimes posologiques associes
CA2859032A1 (fr) * 2011-12-14 2013-06-20 Glaxosmithkline Llc Derives propenoate de la betuline
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
CN103242413B (zh) * 2012-02-08 2015-08-26 江西青峰药业有限公司 Lupane三萜系衍生物及其药学用途
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
MX2015007563A (es) 2012-12-14 2015-10-14 Glaxosmithkline Llc Composiciones farmaceuticas.
WO2014105926A1 (fr) 2012-12-31 2014-07-03 Hetero Research Foundation Nouveaux dérivés proline de l'acide bétulinique utilisés comme inhibiteurs du vih
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
PE20170691A1 (es) 2014-09-26 2017-06-13 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas de accion prolongada
JP2017533937A (ja) * 2014-11-14 2017-11-16 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド オキソルペン誘導体
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (fr) * 2015-03-16 2016-09-22 Hetero Research Foundation Nouveaux triterpénone c-3 avec des dérivés amide c-28 servant d'inhibiteurs de vih
US10669305B2 (en) * 2015-10-13 2020-06-02 Hetero Labs Limited C-3 novel triterpenone with C-28 urea derivatives as HIV inhibitors
CN108699103A (zh) * 2016-01-20 2018-10-23 葛兰素史克知识产权第二有限公司 具有hiv成熟抑制活性的羽扇烷类的胺衍生物
WO2018025247A1 (fr) * 2016-08-05 2018-02-08 Hetero Labs Limited Nouvelle triterpénone en c-3 avec des dérivés de diamide en c-28 en tant qu'inhibiteurs du vih
WO2018029604A1 (fr) * 2016-08-08 2018-02-15 Hetero Labs Limited Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-17 en tant qu'inhibiteurs du vih
WO2018029610A1 (fr) * 2016-08-09 2018-02-15 Hetero Labs Limited Nouvelle triterpénone en c-3 avec des dérivés de n-amide en c-17 en tant qu'inhibiteurs du vih
WO2018065930A1 (fr) * 2016-10-05 2018-04-12 Hetero Labs Limited Triterpénone en c-3 avec des dérivés amides inversés en c-17 en tant qu'inhibiteurs du vih
WO2018069857A1 (fr) * 2016-10-12 2018-04-19 Hetero Labs Limited Nouvelle triterpénone en c-3 à dérivés hétérocycliques d'amide inverse en c-17 utilisés comme inhibiteurs du vih
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
AU2001262489A1 (en) * 2000-05-23 2001-12-03 Univerzita Karlova V Praze Triterpenoid derivatives
US20060019934A1 (en) * 2004-05-20 2006-01-26 Saxena Brij B Anti-HIV-1 activity of betulinol derivatives
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof

Also Published As

Publication number Publication date
EP2250185A4 (fr) 2011-11-16
CA2711424A1 (fr) 2009-07-09
AU2008342537A1 (en) 2009-07-09
MX2010007375A (es) 2010-09-30
CN101981047A (zh) 2011-02-23
WO2009082819A1 (fr) 2009-07-09
JP2011508748A (ja) 2011-03-17
EP2250185A1 (fr) 2010-11-17

Similar Documents

Publication Publication Date Title
WO2009082819A8 (fr) Nouveaux dérivés de lupane
WO2009082818A8 (fr) Préparation de nouveaux dérivés de c-21-céto lupane et leur utilisation
WO2020257549A3 (fr) Composés pour le traitement de maladies pd-l1
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
PH12017501429A1 (en) Derivatives of betulin
WO2017123884A8 (fr) Composés hétérocycliques utilisés comme inhibiteurs du vrs
WO2012142093A3 (fr) Dérivés nucléosides à substitution 2'-cyano et leurs procédés d'utilisation pour traitement de maladies virales
WO2012018534A3 (fr) Composés de biphénylène substitué et procédés d'utilisation desdits composés pour le traitement de maladies virales
TW200728307A (en) Novel spirochromanone derivatives
WO2008154642A3 (fr) Agents antibactériens
WO2008012635A3 (fr) Dérivés d'amines utiles en tant qu'agents anticancéreux
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2009146555A8 (fr) Inhibiteurs de l'intégrase du vih, issus de la pyridoxine
WO2011027249A3 (fr) Dérivés de benzimidazole
WO2012125926A3 (fr) Dérivés tétracycliques de xanthène et leurs méthodes d'utilisation en vue du traitement de maladies virales
WO2010057101A3 (fr) Composés utiles en tant qu’inhibiteurs de vih
WO2009063202A3 (fr) Utilisation de composés antagonistes de crth2
WO2014172188A3 (fr) Composés dérivés de 4-pyridone et leurs utilisations en tant qu'inhibiteurs de la vih intégrase
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
EP2639229A3 (fr) Dérivé de thiazole et son utilisation en tant qu'inhibiteur VAP-1
WO2010132757A3 (fr) Analogues d'aminoglycoside antibactériens
WO2010030704A3 (fr) Analogues d’aminoglycosides antibactériens
NZ600912A (en) Topical use of hydroxytyrosol and derivatives for the prevention of hiv infection
WO2011025982A3 (fr) Composés tétracycline

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880127527.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08869088

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2711424

Country of ref document: CA

Ref document number: 2010540997

Country of ref document: JP

Ref document number: MX/A/2010/007375

Country of ref document: MX

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2574/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008342537

Country of ref document: AU

Ref document number: 586814

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008869088

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2008342537

Country of ref document: AU

Date of ref document: 20081223

Kind code of ref document: A

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载